CTI BioPharma (FRA:CEPS) 3-Year Revenue Growth Rate : 100.90% (As of Mar. 2023)

View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma 3-Year Revenue Growth Rate?

CTI BioPharma's Revenue per Share for the three months ended in Mar. 2023 was €0.17.

During the past 12 months, CTI BioPharma's average Revenue per Share Growth Rate was 2556.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 100.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of CTI BioPharma was 283.30% per year. The lowest was -89.10% per year. And the median was -45.25% per year.

Competitive Comparison of CTI BioPharma's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, CTI BioPharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CTI BioPharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's 3-Year Revenue Growth Rate falls into.

CTI BioPharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

CTI BioPharma (FRA:CEPS) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

CTI BioPharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CTI BioPharma (FRA:CEPS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121

Website

https://www.ctibiopharma.com

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines